MDS pharma has ceased operations at its bioanalytical services
facility in Blainville, Quebec in a bid to boost profitability
after an ongoing investigation of the site by the US Food and Drug
Administration (FDA).
Pfizer's latest cutbacks will provide a new outsourcing opportunity
for contract manufacturing organisations (CMOs) in low-cost
destinations as the drug giant announces plans to double its amount
of drug production outsourcing.
MDS has announced it will help its customers confirm or repeat
analyses done at its contract research facilities in Quebec, after
the Food and Drug Administration (FDA) urged some drug makers to
retest products because of concerns...
Melbourn Scientific has invested in a light obscuration particle
counter to size and count particles in liquid samples using light
microscopy, to expand the company's capacity in stability testing
and to increase throughput and...
India's Dishman Pharmaceuticals & Chemicals is planning to snap
up biotech and nanotech contract research organisation (CRO)
companies in Europe and in the US within drug conjugates to expand
their biologics capability.
LAB Research has completed a $12m facility expansion in Canada that
will increase its preclinical testing services capacity at the site
by 40 per cent.
A number of executives and technical staff at small to medium size
pharmaceutical firms are unaware of how to use their resources
effectively to comply with new EMEA guidelines, designed to
minimise the environmental impact of compounds,...
MDS has been heavily impacted by a US Food and Drug Administration
procedural review of its bioanalytical operations, but still
managed to report quarterly earnings of C$53m (€35m).
AAIPharma has announced it has signed a contract manufacturing
agreement with Mallinckrodt Pharmaceuticals Outsourcing which aims
to provide a "one-stop drug development solution" for drug makers.
Evotec AG has sold its cell analysis instrument division, Evotech
Technologies, to PerkinElmer to allow it to focus more keenly on
its drug discovery pipeline and drug discovery services divisions.
Singapore has successfully completed the first phase of its
biomedical science (BMS) initiative and is now pushing the second
phase forward in order to drive growth in its pharma industry
further.
In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...
Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...
